Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Myers

Gastroenterology Concord, NC Medical Doctor

NPI 1912106998 CMS profile 987251

1070 Vinehaven Dr Ne, Concord, NC 28025

Open in the dashboard

General payments

$12,792

710 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$731,611 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Matthew Myers of Concord, NC is reported in the CMS Open Payments database as having received $12,792 across 710 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $731,611 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 84th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,619 124
2024 General $2,507 129
2023 General $2,178 126
2022 General $1,898 108
2021 General $1,682 98
2020 General $719 43
2019 General $1,189 82

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Myers
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Matthew Myers were reported at $2,619. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Matthew Myers Gastroenterology median Middle half National median
2019 $1,189 $417 $126–$1,100 $163
2020 $719 $224 $74–$624 $114
2021 $1,682 $352 $106–$1,054 $132
2022 $1,898 $448 $129–$1,270 $149
2023 $2,178 $533 $150–$1,390 $160
2024 $2,507 $605 $160–$1,606 $164
2025 $2,619 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,487 141 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,531 91 payments
  3. Janssen Biotech, Inc. $1,345 66 payments
  4. Gilead Sciences, Inc. $1,212 71 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $1,133 60 payments
  6. Pfizer Inc. $501 30 payments
  7. Celgene Corporation $389 30 payments
  8. Alnylam Pharmaceuticals Inc. $385 19 payments
  9. QOL Medical, LLC $354 23 payments
  10. Ferring Pharmaceuticals Inc. $334 21 payments
  11. Other $3,121 158 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,792 710 payments
Products named General payments · program years 2019–2025
  1. XIFAXAN $1,277 75 payments
  2. STELARA $855 47 payments
  3. RINVOQ $778 44 payments
  4. ENTYVIO $642 33 payments
  5. CREON $586 35 payments
  6. TREMFYA $564 23 payments
  7. ZENPEP $536 27 payments
  8. LINZESS $528 29 payments
  9. SKYRIZI $487 29 payments
  10. HUMIRA $479 26 payments
  11. Other $6,933 387 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

887

Median for Gastroenterology: 569

Drug cost

$686,004

Median for Gastroenterology: $104,976

Branded share of claims

36.3%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 19 $518,603
Xifaxan Rifaximin Brand 13 $40,634
Creon Lipase/Protease/Amylase Brand 15 $34,629
Linzess Linaclotide Brand 41 $27,436
Ibsrela Tenapanor Hcl Brand 14 $24,639
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 159 $10,737
Dexlansoprazole Dr Dexlansoprazole Brand 26 $7,081
Mesalamine Generic 38 $5,444
Omeprazole Generic 247 $3,835
Mesalamine Er Mesalamine Brand 12 $3,459

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$181,793

Medicare's payments for the services billed

Medicare patients

308

Average age 73

Services billed

7,107

150 women, 158 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 37%
Ischemic heart disease 31%
Chronic kidney disease 31%
Depression 26%
COPD 22%
Atrial fibrillation 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZENPEP
  • AIMMUNE THERAPEUTICS, INC. $198
$198 — —
RINVOQ
  • AbbVie, Inc. $159
$159 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $156
$156 — —
DUPIXENT
  • GENZYME CORPORATION $92
  • Regeneron Healthcare Solutions, Inc. $56
$148 — —
STELARA
  • Janssen Biotech, Inc. $146
$146 19 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

710 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record